Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.
Tree AC, Ostler P, van der Voet H, Chu W, Loblaw A, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Armstrong J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Duffton A, Brand DH, Henderson D, Morrison K, Brown S, Pugh J, Burnett S, Mahmud M, Hinder V, Naismith O, Hall E, van As N; PACE Trial Investigators. Tree AC, et al. Among authors: staffurth j. Lancet Oncol. 2022 Oct;23(10):1308-1320. doi: 10.1016/S1470-2045(22)00517-4. Epub 2022 Sep 13. Lancet Oncol. 2022. PMID: 36113498 Free article. Clinical Trial.
Intensity-modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: preliminary results of a phase I dose escalation study.
Guerrero Urbano T, Khoo V, Staffurth J, Norman A, Buffa F, Jackson A, Adams E, Hansen V, Clark C, Miles E, McNair H, Nutting C, Parker C, Eeles R, Huddart R, Horwich A, Dearnaley DP. Guerrero Urbano T, et al. Among authors: staffurth j. Clin Oncol (R Coll Radiol). 2010 Apr;22(3):236-44. doi: 10.1016/j.clon.2010.01.005. Epub 2010 Feb 19. Clin Oncol (R Coll Radiol). 2010. PMID: 20171852 Clinical Trial.
Education and training for intensity-modulated radiotherapy in the UK.
Routsis D, Staffurth J, Beardmore C, Mackay R; Radiotherapy Development Board. Routsis D, et al. Among authors: staffurth j. Clin Oncol (R Coll Radiol). 2010 Oct;22(8):675-80. doi: 10.1016/j.clon.2010.06.012. Epub 2010 Jul 22. Clin Oncol (R Coll Radiol). 2010. PMID: 20650617
UK guidelines for the safe delivery of intensity-modulated radiotherapy.
MacKay RI, Staffurth J, Poynter A, Routsis D; Radiotherapy Development Board. MacKay RI, et al. Among authors: staffurth j. Clin Oncol (R Coll Radiol). 2010 Oct;22(8):629-35. doi: 10.1016/j.clon.2010.06.017. Epub 2010 Jul 31. Clin Oncol (R Coll Radiol). 2010. PMID: 20673709
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial.
Dearnaley D, Syndikus I, Sumo G, Bidmead M, Bloomfield D, Clark C, Gao A, Hassan S, Horwich A, Huddart R, Khoo V, Kirkbride P, Mayles H, Mayles P, Naismith O, Parker C, Patterson H, Russell M, Scrase C, South C, Staffurth J, Hall E. Dearnaley D, et al. Among authors: staffurth j. Lancet Oncol. 2012 Jan;13(1):43-54. doi: 10.1016/S1470-2045(11)70293-5. Epub 2011 Dec 12. Lancet Oncol. 2012. PMID: 22169269 Free article. Clinical Trial.
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, Crosby T, Jephcott C, Roy R, Radhakrishna G, McDonald A, Ray R, Joseph G, Staffurth J, Abrams RA, Griffiths G, Maughan T. Mukherjee S, et al. Among authors: staffurth j. Lancet Oncol. 2013 Apr;14(4):317-26. doi: 10.1016/S1470-2045(13)70021-4. Epub 2013 Mar 6. Lancet Oncol. 2013. PMID: 23474363 Free PMC article. Clinical Trial.
175 results